Markets open

Illumina, Inc.

ILMN · NASDAQ-GS

Sep 2026upcoming

Next quarter

Consensus is $1.38 EPS for Sep 2026 across 6 estimates, ranging $1.35 to $1.49.

ILMN Jun 2026

Reported Jul 30, 2026

Beat 6.50%

EPS estimate: $1.23
EPS actual: $1.31
Revenue estimate: —
Revenue actual: —
1-day move: +0.00%

Call highlights have not been generated for this quarter.

Symbol: ILMN
Type: Stock
Sector: Health Care
Industry: Medical Specialities
Country: North America
Exchange: NASDAQ-GS

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Key Issues

Bullish view

Illumina raised its 2026 revenue and earnings outlook after second-quarter results exceeded expectations, indicating that management sees demand and execution improving. Clinical sequencing, NovaSeq X placements and consumables each supported the stronger outlook.

Bearish view

Second-quarter profit still declined year over year, and the stock remains near a 52-week high according to Zacks. The higher outlook therefore needs to translate into sustained earnings growth rather than a one-quarter beat.